Oric Pharmaceuticals has selected a 400-mg dose for its prostate cancer drug rinzimetostat, moving into phase 3 trials. The trial will test the drug with Bayer’s Nubeqa in patients with metastatic castration-resistant prostate cancer. Interim results showed a 33% decline in PSA levels, but Oric’s stock fell 24% due to investor concerns over the dose choice.
